Cargando…
Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment
BACKGROUND: Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Science Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753016/ https://www.ncbi.nlm.nih.gov/pubmed/26918017 http://dx.doi.org/10.11909/j.issn.1671-5411.2016.01.003 |